PDX MODELS IN CLINICAL ONCOLOGY AND CANCER PRECISION MEDICINE 3-5 OCTOBER 2016 Seminar-Hotel Rigi am See Weggis Switzerland
Scientific Programme Each speaker in the programme will be careful to allow enough time for discussion after her/his presentation (at least 5 minutes). Short talks are 10 minutes long, with 7-8 minutes presentation and 2-3 minutes for questions; they will be presented as posters as well, to allow more discussion. MONDAY, OCTOBER 3 15:00-16:00 Registration & Coffee - Setup of Poster Session 1 16:00-16:05 Opening 5 Jos Jonkers (NKI, Amsterdam, The Netherlands) 16:05-17:30 Session 1 - Development of subcutaneous PDX models Chair : Els Hermans (TRACE platform, KU Leuven, Belgium) Sponsored by 16:05 Els Hermans 25 What does it take to build and manage a general Patient-Derived Tumor Xenograft platform in translational cancer research : the experience of Trace 16:30 Andrea Bertotti 25 (University of Torino - Department of Oncology, Italy) Data management for living biobanks : how to deal with dynamic and heterogeneous information 16:55 Sergio Roman-Roman 25 (Institut Curie, Paris, France) Establishing a PDX collection for rare tumour types - The case of uveal melanoma 17:20 Selected short talk : Stefano Cairo 10 (XenTech, Evry, France) Pediatric liver cancer PDX : a preclinical pipeline to identify new treatments for relapsing hepatoblastoma 17:30-17:45 Break 17:45-19:20 Session 2 - Next-Generation PDX Models & Technologies Chair : Rob Clarke (University of Manchester, UK) 17:45 Rob Clarke 10 17:55 Kris Frese 25 (CRUK Manchester Institute, UK) Circulating Tumour Cell-derived explants a new preclinical platform for studying Small Cell Lung Cancer 18:20 Arianna Fumagalli 25 (Hubrecht Institute and UMC Utrecht, The Netherlands) In vivo dissection of the colorectal cancer adenoma-carcinoma sequence by orthotopic transplantion of engineered tumor organoids 18:45 Alberto Villanueva (ICO-IDIBELL and Xenopat, Barcelona, Spain) 25 Orthoxenografts as tools for drug development and real-time personalized oncologic treatments 19:10 Selected short talk : Sebastian Brabetz 10 (German Cancer Research Center (DKFZ), Heidelberg, Germany) Molecular characterisation of orthotopic patient-derived xenograft models of pediatric brain tumours 19:30-21:00 Dinner 21:00-22:30 Poster Session 1 with free drinks
TUESDAY, OCTOBER 4 7 :30-9 :00 Registration & Breakfast 9 :00-10 :30 Session 3 : Modelling the human immune system Chairs : Dominique Vanhecke (Ludwig Institute for Cancer Research at the University of Lausanne) & Joaquín Arribas (Vall d'hebron Institute of Oncology) 9 :00 Dominique Vanhecke & Joaquín Arribas 25 Introduction to current state of the art 9 :25 Ralph Gareus (The Jackson Laboratory) 25 Patient-derived tumor xenografts in humanized NSG-SGM3 mice : a new immuno-oncology platform 9 :50 Johannes Sam 25 (Roche Innovation Center Zürich) Humanised mouse models for drug discovery 10 :15 Selected short talk : Philippe De La Rochère 10 (Institut Curie, Paris, France) Development of new humanized mouse model to study immunotherapies 10 :30-11 :00 Coffee break & Exhibition - End of poster Session 1 11 :00-12 :05 Session 4 : Modelling Cancer Phenotypes Chair : Sergio Roman-Roman (Institut Curie, Paris, France) Sponsored by 11 :00 Sergio Roman-Roman 15 11 :15 Oscar Rueda 25 (CRUK Manchester Institute, UK) Modelling heterogeneity in breast cancer PDTX models 11 :40 Elisabetta Marangoni 25 (Institut Curie, Paris, France) Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy 12 :15-14 :00 Lunch & Exhibition - Setup of Poster Session 2 14 :00-15 :00 Session 4 : Modelling Cancer Phenotypes - To be continued Chair : Sergio Roman-Roman 14 :00 Kristel Kemper 25 (NKI, Amsterdam, The Netherlands) BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts 14 :25 Héctor G. Palmer 25 (Vall d'hebron Institute of Oncology, Barcelona, Spain) Understanding cancer cell dormancy - Strategies to eliminate the hidden seeds of a future relapse 14 :50 Selected short talk : Maria Apicella 10 (Candiolo Cancer Institute IRCCS, University of Torino, Italy) Dual anti-met/egfr therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort 12
15 :00-16 :15 Session 5 : PDX derived tumour cells towards therapeutic testing Chairs : Eva Gonzalez-Suarez (Bellvitge Biomedical Research Institute IDIBELL, Barcelona, Spain) & Silvia Giordano (University of Torino-IRCC, Italy) 15 :00 Eva Gonzalez-Suarez & Silvia Giordano 15 15 :15 Alejandra Bruna 25 (CRUK Cambridge Institute, UK) Derivation of a pharmacogenomic platform for predicting drug responses in breast cancer 15 :40 Hayley Francies 25 (Wellcome Trust Sanger Institute, Hinxton, UK) Towards the next-generation of cancer cell lines : derivation of an organoid biobank 16 :05 Selected short talk : Clare Dempsey 10 (Institute of Cancer Sciences, University of Manchester, UK) 16 :15-16 :45 Coffee break & Exhibition - Setup of Poster Session 2 16 :45-18 :15 Parallel Round Tables : Meet the Experts - Breast cancer models (Chairs : Elisabetta Marangoni, Denis Alférez) - Colorectal cancer models (Chairs : Virginie Dangles-Marie, Andrea Bertotti) - Humanized models (Chairs : Dominique Vanhecke & Joaquín Arribas) - Bioinformatics (Chair : Enzo Medico) 18 :45-21:00 Gala Dinner 21 :00-22 :30 Poster Session 2 with free drinks 13
WEDNESDAY, OCTOBER 5 7 :30-9 :00 Breakfast 9 :00-10 :30 Session 6 : PDX Strategies to inform clinical decision-making - What do we expect? Chairs : Mohamed Bentires-Alj (University of Basel / University Hospital Basel, Basel, Switzerland) & Steven de Jong (UMCG, Groningen, The Netherlands) 9 :00 Momo Bentires-Alj & Steven de Jong 10 9 :10 Mike Lewis 30 (Baylor College of Medicine, Houston, TX, USA) Patient-derived Xenografts As Avatars In Translational Breast Cancer Research 9 :40 Stephane Ferretti 25 (Novartis Institutes for Biomedical Research, Basel, Switzerland) Large scale PDX clinical trial to predict clinical trial drug response 10 :05 Angela M. Davies (Champions Oncology, Hackensack, NJ, USA) 25 Patient-derived xenografts effectively capture patient clinical responses to oncology therapy 10 :30 Selected short talk : Violeta Serra 10 (Vall d'hebron Institute of Oncology, Barcelona, Spain) Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers 10 :45-11 :15 Coffee break & Exhibition - End of poster Session 2 11 :15-12 :15 General discussion Animated by Momo Bentires-Alj, Steven de Jong & Jos Jonkers 12 :15 Best poster prizes 10' Sponsored by Momo Bentires-Alj 12 :25 Closing remarks 10' Jos Jonkers 12 :35-14 :00 Buffet lunch & Departure 15
www.europdx.eu www.europdxworkshop2016.eu Designed by Hugggy